Loading...

Applicability of US Food and Drug Administration Labeling for Dapagliflozin to Patients With Heart Failure With Reduced Ejection Fraction in US Clinical Practice: The Get With the Guidelines–Heart Failure (GWTG-HF) Registry

IMPORTANCE: In May 2020, dapagliflozin was approved by the US Food and Drug Administration (FDA) as the first sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction (HFrEF), based on the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) tr...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:JAMA Cardiol
Main Authors: Vaduganathan, Muthiah, Greene, Stephen J., Zhang, Shuaiqi, Grau-Sepulveda, Maria, DeVore, Adam D., Butler, Javed, Heidenreich, Paul A., Huang, Joanna C., Kittleson, Michelle M., Joynt Maddox, Karen E., McDermott, James J., Owens, Anjali Tiku, Peterson, Pamela N., Solomon, Scott D., Vardeny, Orly, Yancy, Clyde W., Fonarow, Gregg C.
Format: Artigo
Sprog:Inglês
Udgivet: American Medical Association 2020
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7666432/
https://ncbi.nlm.nih.gov/pubmed/33185662
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.5864
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!